AbbVie and Google's Calico strike $1.5bn age-related drug deal
This article was originally published in Scrip
AbbVie and Google's mysterious life sciences company Calico announced a plan to co-invest up to $1.5bn in a research collaboration to develop new therapies that treat age-related diseases, including neurodegeneration and cancer.
You may also be interested in...
Scrip begins its week at the BIO International Convention with interviews and panel discussions about dealmaking and progressing development pipelines. Among the first day highlights: Janssen's hunt for technology, Boehringer's NASH plans and rising investment in neuroscience.
Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.
CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.